CRSP financials
CRISPR Therapeutics AG · end-of-day data as of Nov 13, 2026
CRISPR Therapeutics
$42.24-0.9%
PT $72.45 +71.5%▲ 4
- PT$72.45 +71.5%
- ConsensusBuy · 23
- Bollingerbelow lower
- Sector▲ +15.9%
Neutral
- Earnings in90d
- RSI32
- Support-7.6%
- Resistance+0.3%
- Off 52w high-33.4%
- Volume1.2x
- News0.00
- Trendsideways
- 52w range$42–$63
- ATR+6.3%
- Off ATH-80.8%
▼ 4
- FCF yield-9.3%
- Insiders-$4.88M
- MAs0 of 4
- MACD-0.81
Updates with the 15-min delayed price. Not a forecast or investment advice.
Valuation
- P/E—
- P/E vs own—
- P/E vs sector—
- FCF yield-9.3%
- Market cap$4.1B
Quarterly results
Q3 FY2026: Revenue +1,325.1% year over year, free cash flow -711.2% of revenue, operating margin -1,026.5%.
RevenueFree cash flow
| Q3 FY2026 | Sep 30, 2026 | $12.67M | -1.15 | -$90.1M | -225.9% | -1,026.5% | -879.6% |
| Q2 FY2026 | Jun 30, 2026 | $10.18M | -0.94 | -$86.62M | -337.8% | -1,127.6% | -895.3% |
| Q1 FY2026 | Mar 31, 2026 | $1.46M | -1.28 | -$109M | -3,346.4% | -8,933.3% | -8,431.5% |
| Q4 FY2025 | Dec 31, 2025 | $864K | -1.37 | -$93.07M | -6,770.8% | -17,912.5% | -15,117.2% |
| Q3 FY2025 | Sep 30, 2025 | $889K | -1.17 | -$84.71M | -7,177.1% | -14,854.8% | -11,973.1% |
| Q2 FY2025 | Jun 30, 2025 | $892K | -2.40 | -$114M | -5,477.7% | -14,918.3% | -23,379.9% |
| Q1 FY2025 | Mar 31, 2025 | $865K | -1.58 | -$54.15M | -6,548.4% | -17,158.8% | -15,722.1% |
| Q4 FY2024 | Dec 31, 2024 | $35M | -0.44 | -$50.28M | 100.0% | -184.5% | -106.6% |
| Q3 FY2024 | Sep 30, 2024 | $602K | -1.01 | -$107M | -2,550.0% | -18,294.0% | -14,276.1% |
| Q2 FY2024 | Jun 30, 2024 | $517K | -1.49 | -$96.29M | -10,920.5% | -29,257.3% | -24,450.3% |
| Q1 FY2024 | Mar 31, 2024 | $504K | -1.43 | $109M | -10,177.6% | -27,894.2% | -23,133.1% |
| Q4 FY2023 | Dec 31, 2023 | $200M | 1.10 | -$96.81M | 90.0% | 34.8% | 44.7% |